Iterum Therapeutics plc (ITRMF) Other Non Operating Income (2017 - 2025)

Iterum Therapeutics has reported Other Non Operating Income for 9 years, with the latest figure at -$673000.0 in Q3 2025.

• On a quarterly basis, Other Non Operating Income fell 55.43% year-over-year to -$673000.0 in Q3 2025; TTM through Sep 2025 was -$3.8 million, a 151.47% decrease from a year earlier, with the FY2024 full-year figure at -$3.3 million, down 129.57% from the prior year.
• Other Non Operating Income was -$673000.0 for Q3 2025 at Iterum Therapeutics, down from -$585000.0 in the prior quarter.
• The five-year high for Other Non Operating Income was $15.8 million in Q2 2021, with the low at -$90.1 million in Q1 2021.
• Average Other Non Operating Income over 5 years is -$2.6 million, with a median of -$407000.0 recorded in 2024.
• The largest YoY upside for Other Non Operating Income was 131716.67% in 2021 against a maximum downside of 5466.47% in 2021.
• Over 5 years, Other Non Operating Income stood at $3.6 million in 2021, then retreated by 16.9% to $3.0 million in 2022, then plunged by 110.3% to -$305000.0 in 2023, then slumped by 569.84% to -$2.0 million in 2024, then jumped by 67.06% to -$673000.0 in 2025.
• The last three Other Non Operating Income figures came in at -$673000.0 (Q3 2025), -$585000.0 (Q2 2025), and -$549000.0 (Q1 2025), per Business Quant data.